Fig. 8From: Assessing the epidemiological impact on cervical cancer of switching from 4-valent to 9-valent HPV vaccine within a gender-neutral vaccination programme in SwitzerlandSensitivity analyses results – CIN1 and CIN2/3 incidence cases prevented with the two vaccination strategiesBack to article page